Response to the Letter to the Editor by Bett et al.

Abstract

Response to the Letter to the Editor by Bett et al.TO THE EDITOR: We thank Bett and colleagues for their interest in our review, "Nutritional considerations with antiobesity medications" [1], and we appreciate the opportunity to respond to their letter.Because obesity is a chronic disease, we recognize the importance of long-term data on outcomes of treatment with any antiobesity medication (AOM). A significant body of evidence from randomized controlled trials has supported the efficacy and safety of Food and Drug Administration (FDA)-approved AOMs for chronic weight management, including liraglutide (2014), semaglutide (2021), and tirzepatide (2023). Examples of completed randomized controlled trials of >1 year duration include, but are not limited to, the SCALE